We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Thermo Fisher Scientific and NanoPin: Advancing Infectious Disease Detection Technology
Product News

Thermo Fisher Scientific and NanoPin: Advancing Infectious Disease Detection Technology

Thermo Fisher Scientific and NanoPin: Advancing Infectious Disease Detection Technology
Product News

Thermo Fisher Scientific and NanoPin: Advancing Infectious Disease Detection Technology


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Thermo Fisher Scientific and NanoPin: Advancing Infectious Disease Detection Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Thermo Fisher Scientific and NanoPin Technologies, Inc., the developer of the novel NanoPin diagnostic platform for rapid and quantified results from patient blood samples, have entered into a collaborative relationship to advance blood-based infectious disease detection technology through the development of highly sensitive liquid chromatography mass spectrometry (LC-MS)-based workflows.

Through the detection of disease-related antigens directly from patient blood samples, NanoPin’s diagnostic platform using Thermo Fisher’s advanced LC-MS technology aims to lead to the development of sensitive clinical assays for infectious disease. This could enable healthcare providers to reduce time to results, determine infection stage and monitor patient response to prescribed treatment. The quantified information gleaned from the combined technology could, therefore, support clinical decision-making and the provision of personalized patient care unique to their disease state.

Advertisement